Dermavant Announces First Patient Dosed in Phase 2a Clinical Trial of Topical Dual JAK/Syk Inhibitor Cerdulatinib for Vitiligo

Ads

You May Also Like

American College of Rheumatology Releases First-Ever Rheumatic Disease Report Card

New Report Examines Access, Affordability and Lifestyle Factors Affecting Rheumatic Disease Care in all ...

Insmed Reports Third Quarter 2018 Financial Results and Provides Business Update

—Quarter Highlighted by U.S. FDA Approval of ARIKAYCE® (amikacin liposome inhalation suspension), Followed by ...